stub Cannabis-Based Medicinal Products (CBMPs) Show Potential in Long COVID Treatment -
Connect with us


Cannabis-Based Medicinal Products (CBMPs) Show Potential in Long COVID Treatment




The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had a profound global impact, with millions of lives lost. As our understanding of the virus has evolved, so too has our approach to acute treatment and vaccine development. However, a new challenge has emerged in the form of Long COVID or post COVID-19 syndrome, which affects a significant portion of patients and presents a complex set of symptoms. This article delves into the potential role of cannabis-based medicinal products (CBMPs) in treating the lingering symptoms of Long COVID.

Long COVID: A Persistent Challenge

Long COVID, characterized by symptoms persisting for at least two months after the onset of an acute COVID-19 infection, poses a considerable challenge to healthcare systems worldwide. The symptoms are diverse and can affect various organ systems, including the respiratory, cardiovascular, and neurological systems. Commonly reported symptoms include fatigue, headaches, cognitive dysfunction, sleep disturbances, anxiety, and depression. These symptoms significantly impact the daily lives of those affected, causing difficulties in performing usual activities, reducing exercise levels, and impairing work capacity.

The prevalence of Long COVID varies, and diagnosis can be complicated by differences in recognition, symptom presentation, and variable reporting by healthcare professionals. Estimates suggest that between 10% and 50% of COVID-19 survivors may experience Long COVID, with a higher rate among hospitalized patients. Even individuals who had mild or asymptomatic COVID-19 can develop these persistent symptoms, highlighting the complexity of the condition.

The pathophysiology of Long COVID remains poorly understood but is believed to involve multiple mechanisms, including prolonged inflammation, immune-mediated vascular dysfunction, thromboembolism, and nervous system dysfunction. Endothelial dysfunction, which affects blood vessel health, has been implicated in both acute COVID-19 and Long COVID.

CBMPs and Long COVID

CBMPs, derived from the cannabis plant, encompass a wide range of medicinal preparations. These products may contain various bioactive chemical constituents of the cannabis plant, including cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), terpenes, and flavonoids. These compounds interact with the endocannabinoid system, a neuromodulator system involved in multiple bodily functions.

The constituents of the cannabis plant offer distinct therapeutic benefits, and the entourage effect, where the combined effects of these compounds exceed the sum of individual effects, has been proposed. While much research has focused on CBD and THC, there is a need to explore the roles of minor cannabinoids and other constituents.

Current Evidence for CBMPs in Long COVID Treatment

Several lines of evidence suggest the potential use of CBMPs in treating Long COVID symptoms:

  • Pain Management: CBMPs have demonstrated efficacy in reducing chronic pain, and patients with chronic pain often report improvements in quality of life and reductions in comorbid conditions when using these products. CBMPs have the potential to alleviate headaches and migraines, which are common Long COVID symptoms.
  • Anxiety and Depression: Long COVID can trigger neuropsychiatric symptoms, including anxiety and depression. CBMPs, particularly CBD, have been proposed as potential treatments for anxiety disorders. While more research is needed, observational studies suggest that CBMPs may help alleviate depression symptoms.
  • Fatigue: Fatigue is a prevalent Long COVID symptom, and while research specific to CBMPs and fatigue is limited, CBMPs have been used to manage fatigue in conditions like fibromyalgia.
  • Sleep Disturbances: CBMPs have shown promise in improving sleep quality, a common complaint among Long COVID patients.
  • Cognitive Dysfunction: Cognitive dysfunction is another common Long COVID symptom. While the evidence is limited, some studies suggest that CBMPs, particularly high-CBD formulations, may improve cognitive function.


Long COVID presents a significant and complex challenge with limited treatment options. Current evidence indicates that CBMPs may offer relief for several common Long COVID symptoms, including pain, anxiety, depression, fatigue, sleep disturbances, and cognitive dysfunction.

As research into Long COVID and CBMPs continues, the potential benefits of these products for patients living with Long COVID are promising. Real-world evidence from large-scale databases and observational studies can contribute valuable insights into the effectiveness of CBMPs in managing Long COVID symptoms. Multidisciplinary approaches are essential to advancing our understanding and treatment of Long COVID in real-world clinical practice settings.


Lydia K. (Bsc. RN) is a cannabis writer, which, considering where you’re reading this, makes perfect sense. Currently, she is a regular writer for Mace Media. In the past, she has written for MyBud, RX Leaf & Dine Magazine (Canada), CBDShopy (UK) and Cannavalate & Pharmadiol (Australia). She is best known for writing epic news articles and medical pieces. Occasionally, she deviates from news and science and creates humorous articles. And boy doesn't she love that! She equally enjoys ice cream, as should all right-thinking people.

Warning: Trying to access array offset on value of type bool in /home/customer/www/ on line 830

Warning: Attempt to read property "taxonomy" on null in /home/customer/www/ on line 830